NDA 050791 · Novartis
Myfortic
Mycophenolate Sodium · Oral
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Feb 27, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,244
230 Phase 3, 114 recruiting
FAERS reports
32,732
28,618 serious, 4,507 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY, MALIGNANCIES, AND SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)] . Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Myfortic. Patients receiving Myfortic should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.2)] . Increased risk of development of lymphoma and other malignancies,...
What it is approved for
From the label in effect Jul 29, 2026.
Myfortic is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. ( 1.1 ) Use in combination with cyclosporine and corticosteroids. ( 1.1 ) Limitations of Use : Myfortic delayed-release tablets and mycophenolate mofetil tablets and capsules should not be used interchangeably. ( 1.2 ) 1.1 Prophylaxis of Organ Rejection in Kidney Transplant Myfortic ® (mycophenolic acid) is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Myfortic is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant. Myfortic is to be used in combination with cyclosporine and corticosteroids. 1.2 Limitations of Use Myfortic delayed-release tablets and mycophenolate mofetil (MMF) tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent.
Mechanism: Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways. MPA has cytostatic effects on lymphocytes. Mycophenolate sodium has been shown to prevent the occurrence of acute rejection in rat models of kidney and heart allotransplantation. Mycophenolate...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2004 Original approval · Type 2 - New Active Ingredient Other Important Information from FDAReviewOther
2 products under this application
- MYFORTIC · MYCOPHENOLATE SODIUM EQ 360MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
- MYFORTIC · MYCOPHENOLATE SODIUM EQ 180MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Mycophenolate" as an intervention, any sponsor and status, largest first.
University Hospital, AngersGovernment (non-federal)
NCT02416388 · 3,100 participants (planned) · Start Jan 2015 · Primary completion Jul 30, 2025
Drug: Idarubicin; Daunorubicin and 8 more · For: Acute Myeloid Leukemia (AML)
Sites: Amiens, France; Angers, France; Argenteuil, France · 56 sites in all
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesPivotal-lookingActive, not recruiting
University of Sao Paulo General HospitalAcademic, hospital or other
NCT05879419 · 2,005 participants (planned) · Start May 23, 2023 · Primary completion Dec 1, 2025
Drug: Recombinant Herpes Zoster Vaccine (RZV) · For: Rheumatoid Arthritis; Spondylitis, Ankylosing; Spondyloarthritis and 8 more
Sites: São Paulo, Brazil
- A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney RejectionPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00717470 · 1,252 participants · Start May 14, 2008 · Primary completion Mar 2, 2010
Drug: Prograf®; Advagraf® and 3 more · For: Kidney Transplantation
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Innsbruck, Austria · 110 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
- A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without SteroidsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01304836 · 1,166 participants · Start Jan 22, 2011 · Primary completion May 22, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Kidney Transplantation
Sites: Perth, Australia; Sydney, Australia; Brussels, Belgium · 100 sites in all
- Fixed Dose MMF vs Concentration Controlled MMF After Renal TransplantationPivotal-lookingCompleted
Erasmus Medical CenterAcademic, hospital or other
NCT00166244 · 901 participants · Start May 2003 · Primary completion Mar 2005
Drug: Mycophenolate Mofetil · For: De Novo Renal Transplant Recipient.
Sites: New Lambton, Australia; Brisbane, Australia; Clayton, Australia · 67 sites in all
- Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver TransplantationPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01011205 · 893 participants · Start Sep 30, 2009 · Primary completion Jan 4, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Liver Transplantation
Sites: Buenos Aires, Argentina; Innsbruck, Austria; Minsk, Belarus · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,957
- diarrhoea2,043
- drug ineffective1,894
- death1,451
- pyrexia1,363
- acute kidney injury1,344
- nausea1,239
- fatigue1,076
- covid-191,057
- vomiting1,001
- pneumonia997
- headache990
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 39 |
| 2006 | 82 |
| 2007 | 123 |
| 2008 | 216 |
| 2009 | 268 |
| 2010 | 362 |
| 2011 | 615 |
| 2012 | 629 |
| 2013 | 624 |
| 2014 | 822 |
| 2015 | 1,134 |
| 2016 | 1,324 |
| 2017 | 1,539 |
| 2018 | 1,831 |
| 2019 | 2,108 |
| 2020 | 2,641 |
| 2021 | 2,419 |
| 2022 | 2,959 |
| 2023 | 3,068 |
| 2024 | 3,608 |
| 2025 | 3,839 |
| 2026 | 2,456 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Myfortic (Mycophenolate Sodium)
2024 spending
$1.1M
Beneficiaries
182
756 claims
Per beneficiary
$5,809
$10.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,373,206 |
| 2021 | $1,779,609 |
| 2022 | $1,476,491 |
| 2023 | $1,330,716 |
| 2024 | $1,057,200 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J, Hamadani M, Wu J, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Appel GB, Contreras G, Dooley MA, et al. · J Am Soc Nephrol 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.
Werth VP, Joly P, Mimouni D, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K, Sako M, Oba M, et al. · J Am Soc Nephrol 2022 · Multicenter Study, Randomized Controlled Trial
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP, Roth MD, Clements PJ, et al. · Lancet Respir Med 2016 · Multicenter Study, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.